KALA BIO, Inc.
KALA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479419
No open-market purchases or sales by KALA BIO, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.21M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in KALA BIO, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 108
- +2 vs. Q2 2021
- Shares held
- 30.3M
- −1.64M (−5.1%) vs. Q2 2021
- Total value
- $79.5M
- −$89.7M (−53.0%) vs. Q2 2021
- New holders
- 18
- 31 more added
- Sold out
- 16
- 27 more reduced
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KALA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 15 | $1.21M |
| Q1 2026 | 30 | $294.0K |
| Q4 2025 | 32 | $1.58M |
| Q3 2025 | 24 | $2.69M |
| Q2 2025 | 30 | $17.3M |
| Q1 2025 | 29 | $23.7M |
| Q4 2024 | 33 | $24.0M |
| Q3 2024 | 27 | $12.1M |
| Q2 2024 | 29 | $14.8M |
| Q1 2024 | 29 | $4.88M |
| Q4 2023 | 25 | $3.68M |
| Q3 2023 | 26 | $4.57M |
| Q2 2023 | 30 | $5.56M |
| Q1 2023 | 26 | $4.81M |
| Q4 2022 | 30 | $12.8M |
| Q3 2022 | 56 | $1.36M |
| Q2 2022 | 70 | $2.27M |
| Q1 2022 | 88 | $33.7M |
| Q4 2021 | 85 | $30.9M |
| Q3 2021 | 108 | $79.5M |
| Q2 2021 | 107 | $171.3M |
| Q1 2021 | 118 | $248.9M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding KALA BIO, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Samsara BioCapital, LLC | 601,162 | $1.57M | 0.26% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 933,242 | $2.44M | 0.00% | +179,944+23.9% | Added |
| State Street Corp | 1,111,688 | $2.91M | 0.00% | +289,394+35.2% | Added |
| Caxton Corp | 1,727,751 | $4.53M | 3.67% | +22,902+1.3% | Added |
| Vanguard Group Inc | 2,265,470 | $5.94M | 0.00% | +61,461+2.8% | Added |
| OrbiMed Advisors LLC | 3,438,998 | $9.01M | 0.10% | −2,026,032−37.1% | Reduced |
| BlackRock Inc. | 3,664,849 | $9.60M | 0.00% | −54,563−1.5% | Reduced |
| Ra Capital Management, L.P. | 10,874,613 | $28.5M | 0.39% | 00.0% | Unchanged |
| Jupiter Asset Management Ltd | 0 | $0 | 0.00% | −174,650−100.0% | Sold out |
| Centiva Capital, LP | 0 | $0 | 0.00% | −58,317−100.0% | Sold out |
| Bridgefront Capital, LLC | 0 | $0 | 0.00% | −47,569−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −46,091−100.0% | Sold out |
| Mesirow Financial Investment Management, Inc. | 0 | $0 | 0.00% | −42,104−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −40,823−100.0% | Sold out |
| Manufacturers Life Insurance Company, The | 0 | $0 | 0.00% | −30,389−100.0% | Sold out |
| Mercer Global Advisors Inc | 0 | $0 | 0.00% | −20,370−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −16,644−100.0% | Sold out |
| Winton Group Ltd | 0 | $0 | 0.00% | −15,667−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −11,912−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −10,178−100.0% | Sold out |
| Private Capital Group, LLC | 0 | $0 | 0.00% | −325−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −134−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −44−100.0% | Sold out |
| Pictet Asset Management Ltd | – | – | – | – | Not filed |